Real-world natalizumab biosimilar switching preserved relapsing-remitting MS outcomes but lowered treatment satisfaction, ...
A romosozumab biosimilar showed comparable sclerostin binding and bone-signaling potency to the reference product despite disulfide isoform differences. A romosozumab biosimilar in late-stage ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果